CAR-T cell therapy market

Trophoblast cell surface antigen-2 (TROP-2) is a 35-kDa protein found on cell membranes, made of sugars and a protein chain, serving as a transmitter of calcium signals. It is produced by the TACSTD2 gene and shares a structural similarity with the epithelial cell adhesion molecule (EpCAM). TROP2, although ident...

Gene therapy is an innovative medical approach that manipulates an individual’s genetic material to prevent or treat diseases. It primarily involves introducing, modifying, or substituting genes within a patient’s cells. The central objective of gene therapy is to rectify genetic abnormalities, insert missing genes...

EU Recommends Approval for PTC Therapeutics’ Gene Therapy Upstaza Upstaza, a gene therapy developed by PTC Therapeutics for patients with the genetic condition AADC deficiency, has been recommended for EU approval, putting another test of gene therapy's commercial prospects in the union. Upstaza (eladocagene exu...

Adagio Raises $336 Million to Advance Covid-19 Antibody Treatment An antibody startup Adagio Therapeutics announced the completion of a $336 million Series C financing round. The proceedings from the financing round will be used to augment the development of the company’s lead program developing treatments for C...

As per DelveInsight, the CAR T-Cell Therapy Market size for Non-Hodgkin lymphoma in the 6MM (the US, EU5 (the UK, Germany, France, Italy and Spain)) is expected to be USD 2796.2 Million by 2030. During the course of past decades, with the advancement in technology and a clear understanding of the molecular patho...

DelveInsight estimates by 2030, the Car-T cell therapy market in Acute lymphoblastic leukaemia would approximate to USD 1,315.7 million in the 6MM (U.S. and EU5 including UK, Germany, Italy, France and Spain), emerging as a multi-billion-dollar industry. Acute lymphocytic leukemia (ALL) is a tumor that afflic...